OR51E1 Receptor Antibodies

OR51E1, also known as prostate-specific G-protein-coupled receptor 2 (PSGR2), is an orphan or poorly characterized olfactory receptor belonging to the class A GPCR family. The receptor is expressed predominantly in prostate tissue, particularly in luminal epithelial cells, but has also been detected in several other tissues, including the gastrointestinal tract and certain cancer cells. OR51E1 is frequently overexpressed in prostate cancer and has therefore attracted considerable interest as a potential biomarker and therapeutic target in oncology. Pharmacologically, OR51E1 can respond to several short-chain fatty acids and other volatile metabolites, although its ligand profile is considerably less well defined than that of classical endocrine GPCRs. Propionate and related short-chain fatty acids have been reported to activate OR51E1 and can influence intracellular calcium signaling and downstream kinase pathways. Activation of OR51E1 in prostate cancer cells has been associated with changes in cell proliferation, migration, differentiation and tumor-associated signaling, although the effects appear to depend strongly on cellular context. The receptor has also been implicated in sensing metabolites produced by the microbiota, suggesting a possible link between metabolic signals and prostate or gastrointestinal physiology. No selective clinical-grade OR51E1 agonist or antagonist has been established, and there are currently no approved drugs specifically targeting this receptor. Overall, OR51E1 represents an interesting metabolite-sensing GPCR with potential relevance to prostate cancer and other diseases, but its endogenous ligands, physiological signaling mechanisms and therapeutic potential remain insufficiently characterized.